文献速递骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征糖尿病

肠道菌群代谢物TMAO与减重饮食所致骨密度变化的关系

Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial.
PubMed 文献 · Diabetes Care · 2019-05-21

本研究基于POUNDS Lost试验,纳入264名超重或肥胖且接受DXA骨密度测量的参与者,随机分配至四种不同宏量营养素比例的减重饮食。结果显示,6个月内血浆TMAO下降越多,6个月和2年全身骨密度丢失越多(P=0.03和P=0.02),且2年脊柱骨密度丢失也越多(P=0.005),该关联独立于体重变化,且不受基线糖尿病状态和血糖水平影响。左旋肉碱变化与膳食脂肪摄入在6个月脊柱和髋部骨密度变化上存在交互作用(均P<0.05)。

要点

  • 减重饮食后血浆TMAO下降越多,全身和脊柱骨密度丢失越显著。
  • TMAO与骨密度的关联独立于体重变化和基线糖尿病状态。
  • 左旋肉碱变化与膳食脂肪摄入对骨密度变化存在交互作用。

核心结论

  • TMAO可能对减重期间的骨密度下降具有保护作用,且独立于饮食干预和基线糖尿病风险因素。
  • 膳食脂肪可能改变血浆左旋肉碱变化与骨密度变化之间的关系。

研究设计与样本

  • 基于2年POUNDS Lost随机对照试验的二次分析,纳入264名超重或肥胖且接受DXA骨密度测量的参与者。
  • 参与者被随机分配至四种不同宏量营养素构成的减重饮食,分析汇总及不同饮食组中的关联。

主要发现

  • 基线至6个月血浆TMAO下降越多,6个月和2年全身骨密度丢失越多(P=0.03和P=0.02)。
  • TMAO下降越多与2年脊柱骨密度丢失越多相关(P=0.005),独立于体重变化。
  • 上述关联不受基线糖尿病状态和血糖水平影响。
  • 左旋肉碱变化与膳食脂肪摄入在6个月脊柱和髋部骨密度变化上存在交互作用(均P<0.05)。
  • 左旋肉碱下降最小组中,低脂饮食组较高脂饮食组骨丢失更少(脊柱P=0.03,髋部P=0.02)。

临床怎么用

  • 在减重饮食干预中,监测血浆TMAO和左旋肉碱变化可能有助于评估骨密度丢失风险。
  • 对于糖尿病患者,需关注减重期间TMAO变化与骨健康的关联。
  • 膳食脂肪摄入可能影响左旋肉碱变化与骨密度变化的关系,提示个体化饮食建议需考虑脂肪含量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes is related to obesity and altered bone health, and both are affected by gut microbiota. We examined associations of weight loss diet-induced changes in a gut microbiota-related metabolite trimethylamine N-oxide (TMAO), and its precursors (choline and l-carnitine), with changes in bone mineral density (BMD) considering diabetes-related factors. RESEARCH DESIGN AND METHODS: In the 2-year Preventing Overweight Using Novel Dietary Strategies trial (POUNDS Lost), 264 overweight and obese participants with measurement of BMD by DXA scan were included in the present analysis. The participants were randomly assigned to one of four diets varying in macronutrient intake. Association analysis was performed in pooled participants and different diet groups. Changes in blood levels of TMAO, choline, and l-carnitine from baseline to 6 months after the dietary intervention were calculated. RESULTS: We found that a greater reduction in plasma levels of TMAO from baseline to 6 months was associated with a greater loss in whole-body BMD at 6 months and 2 years (P = 0.03 and P = 0.02). The greater reduction in TMAO was also associated with a greater loss in spine BMD (P = 0.005) at 2 years, independent of body weight changes. The associations were not modified by baseline diabetes status and glycemic levels. Changes in l-carnitine, a precursor of TMAO, showed interactions with dietary fat intake in regard to changes of spine BMD and hip BMD at 6 months (all P < 0.05). Participants with the smallest decrease in l-carnitine showed less bone loss in the low-fat diet group than the high-fat diet group (P spine = 0.03 and P hip = 0.02). CONCLUSIONS: TMAO might protect against BMD reduction during weight loss, independent of diet interventions varying in macronutrient content and baseline diabetes risk factors. Dietary fat may modify the relation between change in plasma l-carnitine level and changes in BMD. Our findings highlight the importance of investigating the relation between TMAO and bone health in patients with diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Zhou T, Heianza Y, Chen Y, et al. Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial. Diabetes Care. 2019. PMID: 31332027. doi:10.2337/dc19-0134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。